

Index

Note: Page numbers in *italics> refer to Figures; those in **bold** to Tables.*

- abnormal liver enzymes, 327
- activities of daily living (ADL), 341, 342, 386, 392, 395
- acupuncture, 101, 295, 296, 312, 316, 443, 456, 471, 555, 559, 560, 563
- AD *see* Alzheimer's disease
- ADEA *see* Australian Diabetes Educators Association (ADEA)
- ADL *see* activities of daily living (ADL)
- ADRAC *see* Australian Adverse Drug Reactions Advisory Committee (ADRAC)
- Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS), 154
- alcohol
 - addiction, 317–19
 - hypoglycaemia, 105
- Alcohol Use Disorders Identification Test (AUDIT), 319
- ALLHAT *see* Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
- alpha-glucosidase inhibitors, 114, 124
- alternative sweeteners, 104–5
- Alzheimer's disease (AD), 394–5
- Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOTBPLA), 153
- antihypertensive agents
 - ACCOMPLISH trial, 158
 - ACE inhibitors, 158
 - beta blockers, side effect, 157–8
 - hypertension, 157
 - long term usage, 158
 - Ramipril, 158
 - types, 159–60
 - zinc deficiency, 158
- Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), 153
- antioxidant therapies, 560
- antiplatelet agents, 160–161
- antipsychotic medicines, 345–6, 347, 473, 547–8
- aromatherapy, 560–561
- ASCOTBPLA *see* Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOTBPLA)
- assessment instruments, 53, 54
- AUDIT *see* Alcohol Use Disorders Identification Test (AUDIT)
- Australian Adverse Drug Reactions Advisory Committee (ADRAC), 215
- Australian Diabetes Educators Association (ADEA), 386
- The Australian National Diabetes Strategy and Implementation Plan*, 474
- autonomic neuropathy
 - diagnosis and management, 267–8
 - gastrointestinal, 266
 - insulin secretion and, 265
 - nursing care, 268–9
 - organs affected, 266
 - Parkinson's disease and Guillain-Barre syndrome, 266
- bariatric surgery, 99–101
- BGATT *see* blood glucose awareness training (BGATT)
- biguanides
 - coeliac disease and, 121
 - metformin, 120
 - possible side effects, 120–121
 - type 2 diabetes, 114
 - vitamin B₁₂ deficiency, 121
- bile acid sequestrants, 328
- blood glucose
 - level
 - equation, 182
 - hypoglycaemic unawareness, 183
 - monitoring, 279, 289

Care of People with Diabetes: A Manual of Nursing Practice, Fourth Edition. Trisha Dunning.
© 2014 John Wiley & Sons, Ltd. Published 2014 by John Wiley & Sons, Ltd.

- blood glucose (*cont'd*)
 - monitoring
 - blood glucose meters, 66–8
 - CGMS *see* continuous glucose monitoring system (CGMS)
 - clinical inertia, 63–4
 - corticosteroid therapy, people, 66
 - factors, blood glucose levels, 64
 - frequency, 64–5
 - home situation, 63
 - hyperglycaemia, 63
 - inaccurate blood glucose results, 70–71
 - insulin infusion, 65
 - patients, diet and exercise, 65
 - patients, oral GLM, 65
 - postprandial hyperglycaemia, 63
 - protocol, hospital settings, 65
 - randomised control trial, type 2, 62
 - ROSSO study, 62
 - testing checklist, 71–2
 - testing frequency, 62
 - TPN guidelines, 66
 - uses, 62–3
 - blood glucose awareness training (BGATT), 353, 493
- brittle diabetes
 - basal bolus regimen, 325
 - causes, 324
 - continuous subcutaneous insulin therapy, 324
 - forms, 323
 - and hyperglycaemia, 210
 - management, 324–5
 - nurse role, 325
 - type 1 diabetes and, 323
- cancer and diabetes
 - CAM and, 311–12
 - care objective, 308–9
 - corticosteroids
 - management, 310–311
 - medications, 307
 - postprandial hyperglycaemia, 310–311
 - lung cancer, 306
 - management, 307
 - nursing responsibilities, 309–10
 - pancreatic cancer, 306
 - proactive cancer screening and prevention programmes, 308
 - radiological imaging, 307
 - risk factors, 306–7
 - screening programmes, 307
- CAPD *see* continuous ambulatory peritoneal dialysis (CAPD)
- cardiovascular disease (CVD)
 - atherosclerosis, 222
 - autonomic neuropathy, 222
 - CAM, 225–7
 - cerebrovascular disease, 233
 - complex metabolic abnormalities, 222
 - depression and, 228–9
 - diabetes-specific cardiovascular abnormalities, 224
 - management considerations, 227–8
 - medicines and
 - ACEI, 226
 - antihypertensive agents, 226
 - antithrombotic medicines, 225–6
 - arrhythmias treatment, 226
 - beta blocking agents, 226
 - choice, 223
 - Framingham and UKPDS risk calculator, 225
 - glucose-lowering medicines, 226
 - lipid-lowering agents, 226
 - mental health and, 228–9
 - nursing responsibilities
 - DIGAMI protocol, 229
 - medical tests/procedures, 231
 - rehabilitation, 231
 - risk factor modification, 231–2
 - Thiazide diuretics, 229–30
 - oestrogen, effect, 222
 - sedentary time, 225
 - signs and symptoms, 234
 - telephone coaching, 233
 - women and, 223
- care models
 - elements, improved outcomes, 45–6
 - internet-based support, 46
 - patient and health professionals, 46–7
 - patient-centred approach, 46
 - patient satisfaction surveys, 46
- care plans
 - data security, 55
 - electronic ‘personalised’ care plan, 55
 - flow charts, 55
 - metabolic status documentation *see* ‘diabetic charts’
 - nursing notes, 55–6
 - standardised, 55
- CBT *see* cognitive behavioural therapy (CBT)
- CFRD *see* cystic fibrosis-related diabetes (CFRD)
- CFT *see* Cystic Fibrosis Trust (CFT)
- chronic hypoglycaemia
 - in older people, 180
 - unawareness, 183
- cirrhosis, 327
- clinical inertia, 63–4
- coeliac disease and diabetes
 - associated diseases, 331–2
 - in children, 331
 - complex immunological response, 331
 - diagnosis, 332–3
 - management, 333
 - signs and symptoms, 332
 - type 1 diabetes and, 331
- cognitive behavioural therapy (CBT), 470–471
- cognitive functioning
 - delirium, 389

- dementia, delirium and depression, 388, 390–391
 - neuronal connections, 388
 - positive and negative factors, cognitive reserve, 388, 389
- communication element, diabetes education
 - empowering education model, 493
 - enhancement, behaviour change, 492–3
 - miscommunication, clinical encounters, 492
 - patient-health professional concordance, 492
 - teaching, 494–5
 - women, 492
- community care, 520, 527, 528
- complementary medicines (CAM)
 - animal studies, 226–7
 - coenzyme Q₁₀, 227
 - commonly used, 553, 554
 - and conventional care, 556–8
 - definition, 554
 - depression, 471
 - diabetic people
 - assistance, 558
 - balance achievement, 558
 - benefits, 559–61
 - herb/medicine interactions, 567
 - menopause management
 - herbal medicines, 457–8
 - phytoestrogens, 456–7
 - nursing responsibilities, 569–70, 570
 - philosophy, 555–6
 - prevalence, 553
 - qualification, 554
 - quality health information identification,
 - internet
 - advertising codes, 571
 - non-sponsored sites, 571
 - reliability assessment, 571
 - self-reflection, 571
 - safety, 568–9
 - sexual problems, 373–4
 - spirituality, 561
 - and surgery
 - before, 562–3
 - adverse events, 563–4
 - after, 563
 - CITES, 567
 - herbs and supplements, 564, 565–6
 - medicine-related safety and quality use, 564
 - weight loss programmes, 101
- conditions associated with diabetes
 - alcohol addiction, 317–19
 - antipsychotic medicines, 345–6
 - breast mastopathy *see* diabetic mastopathy
 - brittle diabetes, 323–5
 - cancer, 306–12
 - CFRD *see* cystic fibrosis-related diabetes (CFRD)
 - coeliac disease, 331–3
 - corticosteroid medications, 342–5
 - driving *see* driving and diabetes
 - enteral and parenteral nutrition *see* enteral and parenteral nutrition
 - fasting (religious observances), 355–6
 - hearing loss, 339–41
 - HIV/AIDS, 338–9
 - illegal drug usage, 319–23
 - liver diseases, 327–30
 - musculoskeletal disorders, 341–2
 - oral health, 325–6
 - sleep disturbance, 335–7
 - smoking, 312–17
 - tuberculosis, 337–8
- continuous ambulatory peritoneal dialysis (CAPD), 248–9
- continuous blood glucose sensors, 142–3
- continuous glucose monitoring system (CGMS)
 - description, 68
 - meters, 69
- continuous positive airway pressure (CPAP) machine, 337
- continuous subcutaneous insulin infusion (CSII)
 - bolus doses, 141
 - pumps, 141
 - structured education programmes, 141
 - surgery, 288–9
 - type 1 diabetes, 142
- corticosteroid and diabetes
 - blood glucose, effect, 342–4
 - classes, 342
 - infection sites monitoring, 344–5
 - insulin, dose flexibility, 343–4
 - management, 344–5
 - and osteoporosis, 345
 - sulphonylureas, 343
- counter-regulatory response
 - adrenaline secretion, 180
 - glucagon, 176–7
 - hormonal response, 181, 211
 - hypoglycaemia, signs and symptoms, 177
 - type 1 and type 2 diabetes, people, 183
- CPAP machine *see* continuous positive airway pressure (CPAP) machine
- C-peptide
 - description, 79
 - as indicator, LADA, 80
- creatinine clearance, 80
- CSII *see* continuous subcutaneous insulin infusion (CSII)
- cystic fibrosis-related diabetes (CFRD)
 - age criteria, 334
 - blood glucose level, 335
 - CFT, 334
 - chloride channels, 334
 - diabetes education, 335
 - diagnosis, 334–5
 - management, 335
 - SIGN guideline, 334
 - signs and symptoms, 335
- Cystic Fibrosis Trust (CFT), 334

- DAFNE *see* Dose Adjustment for Normal Eating (DAFNE)
- DCCT *see* Diabetes Control and Complications Trial (DCCT)
- DCP *see* Diabetes Care Project (DCP)
- dehydration
- care, 394
 - definition, 393
 - forms, 393
 - isotonic and hypotonic, 393
 - risk factors, 393
- dementia, 394–5, 402
- depression
- management
 - antidepressant medicines, 471–2
 - CAM, 471
 - counselling strategies, 470–471
 - IBCT, 471
 - older people, 394
 - screening, 472–3
 - symptoms, 470
- diabetes
- antipsychotic medicines, 473
 - brittle, 210
 - classification, 3–4
 - complications
 - acute, 33
 - long-term, 33–4
 - diabetes mellitus, 2
 - diagnosis
 - checklists, 18
 - HbA1c, 18–19
 - non-pregnant adults, 17, 17
 - OGTT, 17–18
 - urine glucose tests, 17
 - dietary management
 - nurses role, 91–2
 - principles, 94–7
 - DKA *see* diabetic ketoacidosis (DKA)
 - documentation by people, 57–8
 - education, 32
 - education record chart, 499–500
 - exercise/activity, 29, 31–2
 - gestational *see* gestational diabetes (GDM)
 - glucose homeostasis *see* glucose homeostasis
 - management *see* management, diabetes
 - nursing *see* nursing
 - nursing care, people
 - aims, 35
 - complicating factors, 34–5
 - objectives, 36
 - older people *see* older people
 - palliative care *see* palliative care
 - prevalence, 2–3
 - record charts, 56, 57
 - screening, 21, 22
 - type 1 *see* type 1 diabetes
 - type 2 *see* type 2 diabetes
 - women *see* women
- Diabetes Care Project (DCP), 26
- Diabetes Control and Complications Trial (DCCT), 175, 242
- ‘diabetes medicines’ *see* medicines management
- diabetes mellitus
- annual review, 81
 - C-peptide, 79–80
 - creatinine clearance, 80
 - definition, 2
 - glucose monitoring
 - blood *see* blood glucose, monitoring
 - urine *see* urine glucose monitoring
 - ICA, 80
 - management, 25–6
 - management team, 26–7
 - nursing responsibilities
 - blood glucose, 77
 - fructosamines, 78–9
 - glycosylated/glycated haemoglobin, 77–8
 - serum lipids, 79
 - self-care, 80–81
 - self-monitoring, 60
 - status assessment, 76
- Diabetes Prevention Program (DPP), 7, 8, 22
- ‘diabetic charts’
- medication doses, 56
 - purposes, 56
- ‘diabetic grief cycle’, 466, 467
- diabetic ketoacidosis (DKA)
- assessment, 205
 - description, 203
 - differential diagnosis, 204
 - euglycaemic, 210
 - late signs, severe, 203–4
 - metabolic and physiological changes, 204, 206
 - nursing care
 - objectives, 207
 - observations (1–2 hourly), 208–9
 - patient care, 208
 - subsequent care, 209
 - physiology, signs, symptoms and biochemical changes, 203, 205
 - protein catabolism, 203
 - signs, symptoms, and precipitating factors, 203, 204
 - treatment aims, 206
 - unit preparation, 207
- diabetic mastopathy
- autoimmune thyroid disease and cheiroarthropathy, 330
 - breast masses, 330
 - diagnosis, 330
 - management, 331
- diabetogenetic medicines, 546–7
- dietary management
- diet and exercise, 91
 - factors, dietary changes, 101–2
 - goals, 97–8
 - nurses role, 91–2

- obesity, 98–9
- principles, 94–7
- discharge planning
 - admission, 529–30
 - day of discharge, 530
 - transfer, 530
- distractions, 180
- DKA *see* diabetic ketoacidosis (DKA)
- documentation, diabetes education, 505
- Dose Adjustment for Normal Eating (DAFNE), 141
- DPP *see* Diabetes Prevention Program (DPP)
- DPS *see* Finnish Diabetes Prevention Study (DPS)
- driving and diabetes
 - Australian AUSTROADS (2012)
 - standards, 346
 - crashes, prevalence and risk factors
 - falls records, 348
 - insulin treatment, 348
 - mobile phones and distractions, 348
 - older drivers, 346–8
 - PC-simulator, 348–9
 - simulators, hypoglycaemia effect
 - determination, 348
 - traffic crash rate, 346
 - weather and road conditions, 349
 - education programmes and supportive information, 354–5
 - factors affecting, 349, 350–351
 - hypoglycaemia effects
 - BGATT, 353
 - blood glucose level, 352
 - Edinburgh Hypoglycaemia Scale, 352
 - long-acting insulin analogues, 353
 - OHA-induced hypoglycaemia rate, 352
 - UKPDS substudy, 352
 - unawareness, 353
 - safety strategies, 353–4
- ED *see* erectile dysfunction (ED)
- Edelman's model, 490–491
- The Eden Alternative, 396
- education
 - and behaviour theories, 489
 - business models, 490
 - chronic disease management, 485–6
 - communication element, 492–4
 - components, diabetes management programs, 491
 - description, 32
 - divisions
 - basic knowledge, 489–90
 - ongoing education, 490
 - survival skills, 489
 - documentation, 505
 - empowerment *see* empowerment models, diabetes education
 - evaluation, 509–11
 - five-point model, 490–491
 - goal, 484
 - health literacy, 495–8
 - health professional voices, 491
 - holistic patient-centred, 485
 - instruction sheets, 505–9
 - insulin
 - administration, 504
 - delivery systems, 504–5
 - learning styles
 - cognitive process and physical factors, 487
 - self-complete tool, 487, 488
 - and teaching strategies, 487, 487–8
 - types, 487
 - models, behaviour change process, 490
 - nurses' role, 502–4
 - patient-centred care principles, 484–5
 - standardised patient education, 485
 - survival skills, 498–501
 - teaching, 494–5, 502
- emergency department
 - diabetes-related abnormalities, 517
 - nursing responsibilities, 517–18
- empowerment models, diabetes education
 - characteristics, 501
 - shared governance, 501
 - taking control, 501
 - treatment and QoL balance, 501–2
- end of life care *see* palliative care, and end of life care
- enteral and parenteral nutrition
 - administration
 - bolus instillation, 303
 - continuous infusion, 303
 - duodenal and jejunal tubes, 302
 - enteral feeds, 302–3
 - gastroscopy tube, 303
 - gastrostomy (PEG) feeds, 303
 - nasogastric tubes, 302
 - parenteral feeds, 303–4
 - complications, 302
 - formula, choice, 304
 - nursing responsibilities
 - IV and central lines care, 305
 - medication and monitoring, 305–6
 - nasogastric tubes, 304
 - oral feeding care, 306
 - PEG tubes care, 304–5
 - prebiotics and probiotic, 302
 - therapy aim, 301–2
- enteral therapy, 400–401
- ErecAid®, 372
- erectile dysfunction (ED)
 - causes, 370–371
 - definition, 371
 - management
 - and investigation, 371–2
 - involving partners, 374
 - medication, 372
- euglycaemic DKA, 210

- exercise/activity
 - anaerobic and aerobic exercise, 32
 - blood glucose control, 106
 - contributing factor, 181
 - energy sources, 29, 31
 - footwear and clothing, 31
 - fuel utilisation and mobilisation, 185
 - hospitalised person, 32
 - hypoglycaemia, 31
 - hypo-/hyperglycaemia, 106
 - insulin action and, 182
 - strategies, 106–7
- eye disease
 - proliferative retinopathy, 236
 - retinopathy, risk factors
 - age-related macular degeneration, 237
 - glaucoma and cataracts, 236
 - low vision people, aids, 239–40
 - resources for people, 239
 - visually impaired patients, nursing care, 240
 - vision impairment and blindness, 235
- FAI *see* free androgen index (FAI)
- fasting (religious observances)
 - education and counselling, 356
 - potential effects, 355–6
 - Ramadan, 355
- Finnish Diabetes Prevention Study (DPS), 22
- food additives, 105
- food-medicine interactions, 93, 103, 104, 126
- foot ulcers management, 525–6
- free androgen index (FAI), 439
- GDM *see* gestational diabetes (GDM)
- generic and diabetes specific instruments, 53, 54
- genomap and ecomap, 47, 48, 54
- Geriatric Evaluation Units (GEM), 396
- ‘geriatric syndromes’, 388
- gestational diabetes (GDM)
 - description, 15, 448–9
 - diagnosis, 17–19
 - management
 - breastfeeding, 451
 - calorie restriction, 450
 - diet and exercise, 450
 - GLMs, 450
 - insulin, 450, 451
 - MODY, 15–17
 - OGTT, 19–20, 449
 - risk factors, 449–50
- GIP *see* glucose-dependent insulinotropic peptide (GIP)
- GLP-1 agonists *see* glucagon like peptide 1 (GLP-1) agonists
- glucagon
 - administration, guidelines, 193
 - adverse reactions, 194
 - counter-regulatory hormones, 176–7
 - dosage, 193
 - indication, 193
- glucagon like peptide 1 (GLP-1) agonists, 116
- glucose-dependent insulinotropic peptide (GIP), 124–5
- glucose homeostasis, 4–7
- glucose-lowering medicines (GLM)
 - blood glucose control, 229
 - and blood glucose monitoring, 65
 - hypoglycaemia risk, 327, 411, 412
 - and insulin, 127–8, 229, 286
 - oral
 - alpha-glucosidase inhibitors, 114, 124
 - biguanides *see* biguanides
 - blood glucose and HbA_{1c} monitoring, 116
 - blood glucose testing times, 116
 - DPP-4, 116
 - glitnides, 114
 - GLP-1 agonists, 116
 - insulin, 116
 - meglitinides, 114, 122
 - oral hypoglycaemic agents, 117–19
 - SGLT-2, 116
 - sulphonylureas, 114, 121–2
 - type 2 diabetes, 114
 - TZD *see* thiazolidinediones (TZD)
 - renal disease, 245
 - surgery, 281, 283
 - type 2 diabetes, 27, 62, 343
- glucose monitoring
 - blood *see* blood glucose, monitoring
 - urine *see* urine glucose monitoring
- glycaemic targets, 541
- haemochromatosis, 329
- health literacy
 - assessment methods, 497
 - levels, ‘risk factor’ perspective, 496
 - and numeracy skills, 496
 - pamphlets, consulting room, 498
 - readability and usability tests, 496–7
- health status measurement instruments, 53, 54
- hearing loss and diabetes
 - audiology testing, 340
 - autopsy evidence, 339
 - causes, 339–40
 - group education programmes, 340–341
 - in hospital patients, 341
 - management, 340–341
 - pathophysiology, 339
 - signs, 340
- Heart Protection Study, 153
- hepatic encephalopathy, 328
- hepatocellular carcinoma, 328
- herb/medicine interactions, 567
- HHS *see* hyperosmolar hyperglycaemia states (HHS)
- HIV/AIDS
 - blood glucose monitoring, 339
 - deficient immune status, 338

- high viral load, 339
- hyperglycaemia management, 339
- management, 338–9
- medicine selection, 338
- Megestrol acetate, 338
- people groups, 338
- holistic assessment
 - care models, 45–7
 - care plans *see* care plans
 - documentation, 54–5, 57–8
 - instruments, health status measurement, 53, 54
 - nursing *see* holistic nursing
- holistic nursing
 - beliefs and attitude, patient, 45
 - characteristics
 - discharge/transition, 49
 - electronic data collection and management process, 49
 - genomap and ecomap, type 2 diabetes, 47, 48
 - health ‘problem list’, 49
 - physical disability, 49
 - ‘story listening’, 47
 - healing, 45
 - patient assessment chart, 49–53
 - responsibilities, 56–7
- home-based care
 - advice, 521
 - blood glucose level interpretation, 522
 - chest pain, 524
 - diabetes-related care, 520–521
 - diabetic foot ulcers management, 525–6
 - disposal, sharps, 527
 - follow-up visit, 525
 - hyperglycaemia, 523–4
 - hypoglycaemia, 523
 - insulin storage, 528
 - missed medication dose, 524–5
 - ‘non-compliant’, 526–7
 - nursing actions, 522
 - problems, diabetes-related, 521–2
- hormone replacement therapy (HRT), 373, 453–4
- HRT *see* hormone replacement therapy (HRT)
- The Hydration Assessment checklist, 399
- hyperglycaemia
 - description, 201
 - fluid resuscitation, 201
 - glucose, 220
 - home-based care, 523–4
 - intensive insulin therapy, 201
 - laboratory/capillary blood glucose tests, 203
 - and macrovascular disease, 220
 - palliative situations, 542
- hyperosmolar hyperglycaemia states (HHS)
 - description, 211
 - insulin deficiency, 211–12
 - signs and symptoms, 212–13, 214
- HYPOA-Q *see* Hypoglycaemia Awareness Questionnaire (HYPOA-Q)
- hypoglycaemia
 - adverse reactions, 194
 - autonomic nervous system, activation, 177
 - care objectives, 188
 - causes, 181–2
 - in children, 176
 - consequences, 192
 - counter-regulatory hormonal response, 176–7, 181, 181
 - DARTS study, 176
 - definition, 178–80
 - education programmes, 177
 - emotions, 177
 - glucagon
 - administration, guidelines, 193
 - counter-regulatory hormones, 176–8
 - home-based care, 523
 - medicine interactions, 187
 - nocturnal, 184–7
 - older people
 - counter-regulatory response, 411
 - management, 412
 - risk factors, 412
 - vaccinations, 413
 - oral GLMs, 178
 - palliative situations, 542–3
 - prevention and management, 182–3
 - prolonged, 189–90
 - psychological effects, 191–2
 - recognition, 180–181
 - relative, 187
 - risk, 179–80, 190–191
 - signs and symptoms, 179
 - treatment, 188–9
 - unawareness
 - counter-regulatory response, 183
 - prevalence, 183–4
- Hypoglycaemia Awareness Questionnaire (HYPOA-Q), 184
- hypoglycaemic unawareness
 - blood glucose level, 183
 - clinical trial methods, 184
 - medicines, 183
 - prevalence, 183–4
- IBCT *see* interactive behaviour change technology (IBCT)
- ICA *see* islet cell antibodies (ICA)
- illegal drug usage
 - administration routes, 321
 - cardiovascular effect, 321
 - categories, 319–20
 - drug abuse and drug addiction, criteria, 312
 - effects, 321–2
 - herbs, psychogenic properties, 320–321
 - management issues, 320, 322–3
 - medicines interactions, 322

- IM *see* integrative medicine (IM)
- incretin hormones
 - DPP-4 inhibitor analogues, 125
 - GIP, 124–5
 - glucagon-like peptide (GLP-1), 125
 - side effects, 125
- Index of Sexual Life (ISL), 374
- information sheet, oral glucose tolerance test, 20
- instruction sheets
 - diabetes management, 506–9
 - drawing up insulin, 505–6
 - insulin injection, 506
- insulin
 - action, 134
 - administration, 504
 - allergy, 147–8
 - animal, 134
 - binding and signalling, 13
 - biphasic, 136
 - continuous blood glucose sensors, 142–3
 - CSII *see* continuous subcutaneous insulin infusion (CSII)
 - deficiency, 3, 8
 - delivery systems, 504–5
 - dose adjustment, hypoglycaemia, 182
 - Glargine, long-acting analogues, 134
 - high risk medicines, 134
 - infusions, usage, 145–7
 - injection sites and administration, 137–8
 - intermediate-acting, 135
 - Levemir, long-acting analogues, 134
 - long-acting, 136
 - mixing short-and intermediate-acting, 138
 - ‘mix insulins’, 138
 - morning hyperglycaemia, interpretation
 - ‘Dawn phenomenon’, 141
 - insufficient basal insulin, 140
 - Somogyi effect, 141
 - objectives, therapy, 134
 - outpatient stabilisation, protocol, 166–7
 - person, 182
 - rapid-acting, 135
 - regimens
 - basal bolus, 139–40
 - BD (basal daily), 139
 - daily injection, 139
 - diagrammatic representation, 139
 - release, 4
 - resistance syndrome, 11, 12
 - short-acting, 135
 - storing, 136
 - subcutaneous
 - intravenous infusions, 144–5
 - sliding scales, 143
 - solution preparation, 145
 - top-up or stat doses, 143
 - therapy initiation
 - advice and written information, 133
 - barriers, 132
 - ‘clinical inertia’, 132
 - health professionals acknowledgment, 132
 - person’s concerns, 133
 - timing, 133
 - visual changes, 133
 - weight and blood glucose, strategies for, 133
 - type 2 diabetes *see* type 2 diabetes, insulin
 - initiation
 - ultra-long acting, 136
 - insulin transformation products (ITP), 136
 - integrative medicine (IM), 124, 137, 189, 504, 523, 552, 556
 - intensive care (ICU), 519
 - interactive behaviour change technology (IBCT), 471
 - International Diabetes Federation (IDF), 227
 - International Society for Paediatric and Adolescent Diabetes (ISPAD), 332
 - investigative procedures
 - care objectives, 291
 - clear written instructions, 291
 - complementary therapies and surgery, 295
 - eye procedures
 - nursing responsibilities, 293–4
 - patient care, fluorescein angiography, 292–3
 - photocoagulation goals, 293
 - radio-contrast media injection, patient, 294–5
 - retinal cameras, 292
 - management protocols, 291
 - metabolic stress, 290
 - nursing care, implications, 297
 - nursing management, 291–2
 - PET scans, 291
 - postoperative phase, 296–7
 - preoperative phase, 295–6
 - ISL *see* Index of Sexual Life (ISL)
 - islet cell antibodies (ICA), 80
 - ISPAD *see* International Society for Paediatric and Adolescent Diabetes (ISPAD)
 - ITP *see* insulin transformation products (ITP)
 - lactic acidosis
 - definition, 213
 - excess lactate, 214
 - management, 215
 - and Metformin, 215
 - signs and symptoms, 214
 - LADA *see* latent autoimmune diabetes (LADA)
 - LAGB *see* laparoscopic adjustable gastric banding (LAGB)
 - laparoscopic adjustable gastric banding (LAGB), 290
 - latent autoimmune diabetes (LADA)
 - description, 10
 - management, 10–11
 - lipid lowering agents
 - cardiovascular prevention trials, 153–4
 - classes, 155, 156

- HDL-c, 153
- individual risk assessment, 155
- LDL cholesterol, 153
- management strategies, 155
- side effects, 155–7
- statins, 153, 155
- lipid medicines, monitoring, 157
- liver disease and diabetes
 - alcohol consumption, 328
 - bile acid sequestrants, 328
 - CAM medicines, 329
 - diet and exercise, 328
 - haemochromatosis, 329
 - hepatitis C medication, 328
 - iron overload, 330
 - management, 330
 - managing people, 328
 - type 2 diabetes *see* type 2 diabetes
- long-term complications
 - autonomic neuropathy *see* autonomic neuropathy
 - cardiovascular disease *see* cardiovascular disease (CVD)
 - chronic conditions, 219
 - classification, 219
 - diabetes complications, pathophysiology
 - AGE formation, 220–221
 - antioxidant agents, 220
 - coenzyme Q10 (CQ-10), 220
 - hexosamine pathway, flux increase, 221
 - hyperglycaemia, 220
 - PKC isoforms activation, 221
 - polyol pathway, flux increase, 221
 - eye disease *see* eye disease
 - multimorbidity, 219
 - peripheral neuropathy *see* peripheral neuropathy
 - renal disease *see* renal disease
- management, diabetes
 - adolescents, 425
 - aims
 - blood glucose range, 27
 - model, 29, 30
 - person-centred empowerment model, 27–8
 - targets, 27, 28
 - testing pattern, blood glucose, 29
 - care aspects, 425–6
 - children
 - and adolescents, 425
 - complementary therapy in, 432–3
 - gluten-containing foods, 424
 - ketoacidosis in, 434
 - medicine-related information, 431
 - morbidity and mortality rates, 424
 - ‘thrifty gene’, 423
 - TRIGIR study, 424
 - type 1 diabetes, 423
 - type 2 diabetes, 423–4, 430
 - conditions associated, 431–2
 - diabetes mellitus, 25–6
 - family support, 422
 - investigative procedures *see* investigative procedures
 - self-management, medication, 431
 - strategies and consultation techniques, 433–4
 - surgical procedures *see* surgical procedures
 - team, 26–7
 - technology, 36–7
 - type 1 diabetes *see* type 1 diabetes, management
- maternal hyperglycaemia, 448
- maturity onset diabetes of the young (MODY)
 - description, 15
 - GLMs, 16
 - single gene mutations, 16
- medicines management
 - antiplatelet agents *see* antiplatelet agents
 - cardiovascular agents, 112
 - enteral feeds, 401–2
 - incretin hormones *see* incretin hormones
 - insulin *see* insulin
 - interactions
 - GLMs and insulin, interaction, 127–8
 - glucose-lowering medicines and prescribed medicines, 127
 - mechanisms, 126
 - potential medicine and herb, 126
 - lipid lowering agents *see* lipid lowering agents
 - oral GLM *see* glucose-lowering medicines (GLM), oral
 - QUM *see* quality use of medicines (QUM)
 - safety, adherence and self-management
 - adherence, 163–4
 - medicine non-adherence, 163
 - MEMs medicine containers, 165
 - patient-centred medication self-management, 164–5
 - patient non-adherence, 162
 - polypharmacy, 161–2
 - reducing errors, strategies, 161
- meglitinides, 114, 122
- menopausal hormone therapy (MHT), 454
- menopause
 - CAM
 - herbal medicines, 457–8
 - phytoestrogens, 456–7
 - management
 - antibiotics and antifungal agents, 454
 - blood glucose monitoring, 453
 - complementary approaches, 456–8
 - HRT, 453–4
 - signs and symptoms, 453
- metabolic control, older people
 - access and equity, services, 405
 - exercise/activity, 410–411
 - hypoglycaemia, 411–13
 - infection, 405–6

- menopause (*cont'd*)
 - and management, 404, 405
 - nursing care, 413–14
 - pharmacovigilance, 409–10
 - QoL, 406–7
 - safety, 407–9
- metabolic syndrome
 - children and adolescents, 7–8
 - description, 5
 - key features, 5–7
- MHT *see* menopausal hormone therapy (MHT)
- mild hypoglycaemia, 188–9
- Mini Nutritional assessment (MNA), 399
- MNA *see* Mini Nutritional assessment (MNA)
- MODY *see* maturity onset diabetes of the young (MODY)
- musculoskeletal diseases
 - causal mechanisms, 341
 - chronic hyperglycaemia and, 341
 - glucose homeostasis, multisystem effects, 341
 - strength and flexibility training programmes, 342
- NAFLD *see* non-alcoholic fatty liver disease (NAFLD)
- neonatal hypoglycaemia, 447
- nocturnal hypoglycaemia
 - indicators, 185
 - management, 186–7
 - repeated, 185
 - risk factor, 185
 - Somogyi effect and, 185–6
 - Terbutaline, 186–7
- non-alcoholic fatty liver disease (NAFLD), 327
- nursing *see also* holistic nursing
 - autonomic neuropathy, 268–9
 - complicating factors, 34–5
 - diabetic ketoacidosis (DKA)
 - objectives, 207
 - observations (1–2 hourly), 208–9
 - patient care, 208
 - subsequent care, 209
 - health assessment chart, 49–53
 - history, 49
 - objectives, 36
 - responsibilities
 - cancer and diabetes, 309–10
 - complementary medicines (CAM), 569–70, 570
 - CVD, 229–32
 - diabetes mellitus, 77–9
 - diabetes record charts, 56, 57
 - emergency department, 517–18
 - enteral and parenteral nutrition, 304–6
 - eye procedures, 293–4
 - nutrition, 102–7
 - nutrition, obesity and exercise, 102, 104–7
 - outpatient department, 519–20
 - peripheral neuropathy, 260–262
 - renal disease, 250
 - stabilisation, diabetes, 149–50
- nutrition
 - dietary management *see* dietary management
 - inadequate, 85
 - malnutrition and under-nutrition, 91–2
 - nursing responsibilities, 102–7
 - obesity and stress, 88
 - oxidative tissue damage, 85
 - screening methods
 - dietary characteristics, 93–4
 - nutritional status, 93
- nutritional management, older people
 - biochemical assessments, 399
 - caloric requirements, 398
 - Hydration Assessment checklist, 399
 - indicators, malnutrition, 399
 - malnourishment, 398–9
- obesity
 - bariatric surgery, 99–101
 - CAM, 101
 - definition, 85
 - and diabetes management, 90
 - dietary management, 98–9
 - environmental factors, 85
 - medicines, 85
 - ‘obesity paradox’, 85
 - pathogenesis
 - adipokines and changes, abdomen, 86, 86
 - adipose tissue, 87
 - CRB neuroregulatory system, 86–7
 - preventative health care interventions, 87
 - significance, abdominal obesity, 87–8
 - and stress, 88
 - type 2 diabetes, 85
 - weight measurement
 - BMI, 89
 - crude weight, 89
 - dietary recall, 89
 - FFQ, 89
 - food records, 89
 - plate waste methodology, 90
 - visual estimation, 89–90
 - WHR, 89
- OGTT *see* oral glucose tolerance test (OGTT)
- older people
 - ADEA, 386
 - ageing
 - description, 380
 - theories, 380, 381
 - cognitive functioning *see* cognitive functioning
 - dehydration, 392–4
 - dementia *see* dementia
 - depression, 394
 - diabetes management
 - aims, 396
 - The Eden Alternative, 396
 - enteral therapy, 400–401

- factors, 396–7
 - nutritional, 397–9
 - suboptimal metabolic control, 395
 - education, diabetes, 402–3
 - enteral feeds, 401–2
 - fasting blood glucose, 385
 - functional status
 - determination, 386–7
 - maintenance, 384
 - ‘geriatric syndromes’, 388
 - illnesses, atypical symptoms, 385
 - metabolic control *see* metabolic control, older people
 - problems, 381, 382–4
 - self-care, 403–4
 - wellness maintenance, 380–381
- oral GLM *see* glucose-lowering medicines (GLM), oral
- oral glucose tolerance test (OGTT)
- description, 19
 - information sheet, 20
 - rationale, 19–20
 - test protocol, 20–21
- oral health and diabetes
- ageing and, 326
 - causal mechanisms, 326
 - management, 326
 - oral candidiasis, 325
 - ‘sixth diabetes complication’, 325
 - symptoms, 325
- Oslo Diet and Exercise Program, 22
- outpatient department, nursing responsibilities, 519–20
- palliative care
- antipsychotic medicines, 547–8
 - blood glucose monitoring, 541
 - corticosteroid-induced diabetes management, 547
 - definition, 533
 - diabetes management, 540–541
 - diabetogenetic medicines, 546–7
 - dying, 533
 - education, 549
 - and end of life care
 - ACP, 537
 - blood glucose monitoring and GLMs, 534
 - common symptoms, 534, 536–7
 - PCA, 537
 - QUM framework, 535
 - symptom burden, 538
 - family/carers, 548
 - glycaemic targets, 541
 - guiding philosophy, 534
 - hyperglycaemia, 542
 - hypoglycaemia, 542–3
 - medicine management, 543
 - nutrition and hydration, 545–6
 - PCOC, 538, 539
 - type 1 diabetes, 543–4
 - type 2 diabetes
 - antihypertensive and lipid lowering medicines, 545
 - CAM, 545
 - incretins, 544
 - insulin, 544–5
 - metformin, 544
 - SGLT-2, 545
 - sulphonylureas, 544
 - thiazolidinediones, 544
 - withdrawing treatment, 548–9
- Palliative Care Australia (PCA), 537
- Palliative Care Outcome Collaborative (PCOC), 538, 539
- ‘patient non-compliance’, 182
- PCA *see* Palliative Care Australia (PCA)
- PCOC *see* Palliative Care Outcome Collaborative (PCOC)
- PCOS *see* polycystic ovarian syndrome (PCOS)
- PDE-5 medicines *see* phosphodiesterase type 5 (PDE-5) medicines
- peripheral neuropathy
- ageing and feet changes, 259
 - amputation rate, 254
 - care objective, 260
 - diabetes-related, 257–8
 - diabetic foot disease, 254
 - foot problems development, risk factor, 254, 259, 259–60
 - foot ulcers classification, 262
 - hyperbaric oxygen, 264
 - infection, 255–7
 - medicine, 256, 257
 - nursing responsibilities, 260–262
 - pain management strategies, 258–9
 - rehabilitation, 264–5
 - self care and care in hospital, 254
 - stages, 259
 - vascular changes, 254
 - wound management, 262–4, 263
- Permission-Limited Information-Specific Suggestions-Intensive Therapy (PLISSIT) model, 376–7
- Pharmaceutical Health And Rational use of Medicines (PHARM) Committee, 115
- phosphodiesterase type 5 (PDE-5) medicines, 372
- PLISSIT model *see* Permission-Limited Information-Specific Suggestions-Intensive Therapy (PLISSIT) model
- PN *see* practice nurses (PN)
- polycystic ovarian syndrome (PCOS)
- antiandrogens, 441
 - antipsychotic medicines, 442
 - diet and exercise, 441, 442
 - endometrial hyperplasia, 441
 - FAI, 439
 - insulin resistance, 429
 - Metformin, 441

- polycystic ovarian syndrome (*cont'd*)
 - OC, 441
 - PCOS Association of Australia, 440
 - risk factors, 439, 440
 - screening tools, 441
 - tailored psychotherapy, 442
 - weight loss, 440
- postprandial hyperglycaemia, 63
- practice nurses (PN), 528–9
- pregnancy
 - complications, 446–7
 - diabetes effect, baby, 447–8
 - hyperglycaemia effect, child, 448
 - insulin sensitivity, 442
 - management
 - medication, 443, 444
 - strategies, 443, 445–6
 - prepregnancy counselling, 442
- psychological distress and disorders
 - antipsychotic medicines and diabetes, 473
 - and cardiovascular disease, 476–7
 - compliance/adherence/concordance, 475–6
 - coping issues, young people, 466
 - depression *see* depression
 - ‘diabetic grief cycle’, 466, 467
 - health professional factors, 465
 - individual factors, 464–5
 - resilience, 466
 - screening, 472–3
 - self-care, 465–6
 - social factors, 464
 - spirituality, 468
 - type 1 diabetes, 473–4
 - type 2 diabetes, 474–5
- QoL *see* quality of life (QoL)
- quality of life (QoL)
 - cognitive functioning, 406
 - demographic factors, 407
 - description, 54, 406, 478
 - determinant categories, 478
 - and healing, 478
 - health and medical issues, 406
 - management strategies, 406
 - measurement, 478–9
 - mental and physical well being, 479
- quality use of medicines (QUM)
 - description, 536
 - and diabetes
 - areas, 113
 - clinical trials, 113
 - diabetes complications, 113
 - polypharmacy, 113
 - process, PHARM committee, 115
 - end of life care, 535
 - PHARM committee, 112
 - responsibility, 112
- QUM *see* quality use of medicines (QUM)
- renal disease
 - and anaemia, 245
 - CAPD in patients on insulin, 250–251
 - care objectives, 249–50
 - chronic kidney disease, stages, 241
 - diabetic nephropathy, 241
 - diet and, 245–7
 - failure
 - ACE inhibitors, 244
 - ‘Choosing Wisely’ campaign, 245
 - CIN and, 244
 - interoperative hyperglycaemia association, 244
 - issues associated, 243
 - morbidity and mortality, 244
 - and herbal medicine, 252–3
 - kidney biopsy, 247
 - nursing responsibilities, 250
 - older people and, 247
 - patients education, CAPD, 251–2
 - proteinuria, 241
 - renal dialysis
 - CAPD, 248–9
 - haemodialysis, 247–8
 - peritoneal dialysis, 248
 - treatment priorities, 249
 - risk factor
 - gender, 242
 - hyperglycaemia, 242
 - microalbuminuria and proteinuria presence, 242
 - retinopathy, 242
 - smoking, 242
 - supportive care, 252
- SACN *see* Scientific Advisory Committee on Nutrition (SACN)
- Saxagliptin, 125
- Scientific Advisory Committee on Nutrition (SACN), 424
- severe hypoglycaemia, 189
- sexual and reproductive health
 - contraception, 366–7
 - counselling, 374–6
 - and development, 367
 - difficulties and dysfunction
 - chronic disease sequelae, 368–9
 - environmental factors, 369
 - individual factors, 368
 - interpersonal factors, 368
 - investigation and management, 371–2
- men
 - ED *see* erectile dysfunction (ED)
 - lowered sperm counts, 371
 - non-pharmacological therapy, 372–3
 - nurse, 377
 - and older people, 369
 - problems, 367
 - women

- fluctuating blood glucose levels, 370
 - planning sex education and counselling, 370
 - type 2 diabetes, 369–70
- SGLT-2 *see* sodium-glucose cotransporter-2 (SGLT-2)
- Sitagliptin, 125
- sleep disturbance
 - CPAP machine, 337
 - diagnosis, 336
 - management, 337
 - obstructive sleep apnoea, 335–6
 - oxygen desaturation index (ODI), 336
 - quality slow wave sleep, 336
 - shift workers and, 335–6
- smoking
 - 5As approach to stop, 315–16
 - associated diseases, 313
 - CAM strategies, 316
 - cardiovascular disease risk factor, 313
 - cessation programmes, 314
 - general practitioners (GPs), assistance, 315–17
 - medicines, support cessation, 317, 318
 - nicotine addiction, 314–15
 - prescribed medicine and tobacco, 313
 - quitting, 314
 - respiratory diseases and, 313
 - self-help websites, 316
 - smokeless tobacco products, 317
 - tobacco, 313
 - withdrawal symptoms, 315
- sodium-glucose cotransporter-2 (SGLT-2)
 - inhibitors, 125–6
 - oral GLM, 116
 - palliative care, 545
- stabilisation, diabetes
 - community and outpatient, 150–151
 - in hospital, 149
 - nursing responsibilities, 149–50
 - outpatient stabilisation, protocol, 166–7
 - patient criteria, 151
 - process, 152
- steatohepatitis, 330
- St John's Wort, 560
- sugar-free foods, 104
- sulphonylureas
 - action, 121
 - hypoglycaemia, 121
 - and hypoglycaemia, 179
 - metformin and, 121
 - morbidity and mortality, 182
 - oral GLM, 114
 - possible side effects, 121–2
 - pregnancy and, 122
- surgical procedures
 - anaesthesia and surgery, 277–8
 - bariatric surgery, 290
 - children with diabetes, 279
 - emergency procedures, 289–90
 - gastric autonomic neuropathy, 279
 - gastric banding, 290
 - hormonal, metabolic, and long-term effects, 278
 - major procedures, operation day
 - blood glucose monitoring, 285
 - dehydration, clinical signs, 284
 - diabetic patient, guidelines, 285
 - fluid replacement, 284
 - premedication and routine preparation, 284
 - management aim, 280–281
 - minor procedures
 - informing patients, guidelines, 287–8
 - insulin pump therapy, 288–9
 - obesity, 279
 - older people with diabetes, 280
 - postoperative nursing responsibilities
 - immediate care, 286
 - ongoing care, 287
 - preoperative nursing care
 - chlorpropamide, 283
 - diabetic complications, 282–3
 - individual's blood glucose profile, 281
 - metformin, 283
 - nursing actions, 281–4
 - preadmission clinics, 281
 - stress response, 278
 - survival skills, diabetes education
 - description, 498
 - diabetes education record chart, 499–500
 - ongoing education, 500–501
- Tai Chi, 559–60
- thiazolidinediones (TZD)
 - bladder cancer risk, 123
 - DREAM data, 122–3
 - oral GLM, 114
 - pioglitazone, 122–3
 - rosiglitazone, 122
 - side effects, 123–4
- tuberculosis (TB) and diabetes, 337–8
- type 1 diabetes
 - characteristics, 14
 - children, 9
 - description, 8
 - EURODIAB sub-study 2, 9
 - exogenous factors, 9
 - hypoglycaemia, 474
 - LADA *see* latent autoimmune diabetes (LADA)
 - management
 - aggressive antisocial conduct, 429
 - autoimmune diseases screening, 427
 - basal bolus regimens, 427
 - dietary restrictions, 428
 - eating disorders, 429
 - glucagon response, 428
 - hypoglycaemia, 427
 - Internet support, 430
 - menarche effect, 429
 - paediatric depression, 429

- type 1 diabetes (*cont'd*)
 - PCOS, 429
 - self-management expectations, 428
 - prevention, 25
 - progression, 9, 10
 - symptoms, 8, 9
 - women, 451–2
- type 2 diabetes
 - anxiety, 475
 - characteristics, 14
 - DAWN study, 475
 - genomap and ecomap, 47, 48
 - indigenous children and adolescents, 15
 - insulin, 474
 - insulin initiation
 - administration time, 129
 - barriers, 132–3
 - blood glucose targets achievement, algorithm, 131
 - clinical observations, 128
 - community-based insulin initiation, 130
 - dose regimens, 130, 131
 - indications, 129
 - individual health services, 129–30
 - INITIATE study, 130
 - Novorapid, 130
 - 1-2-3 study, 130
 - 'tablet failure', 128
 - Treat-to-Target study, 130
 - insulin resistance, 11, 12
 - insulin signalling and glucose transport, 12, 13
 - liver disease
 - abnormal liver enzymes, 327
 - acute liver failure, 328
 - cirrhosis, 327
 - hepatic encephalopathy, 328
 - hepatocellular carcinoma, 328
 - NAFLD, 327
 - medicines
 - antibody 2H10, 126
 - SGLT2 inhibitors, 125–6
 - predictors, 12
 - prevention, 22–4
 - SFRP4, 13
 - tools and risk calculators, 12
 - women, 452
- TZD *see* thiazolidinediones (TZD)
- urine glucose monitoring
 - glycosuria, 73
 - indications, 74
 - kidney function monitoring, 74
 - microalbuminuria screening methods, 75–6
 - renal threshold, glucose, 73–4
- VA-HIT *see* Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial (VA-HIT)
- vascular dementia (VD), 394–5
- VD *see* vascular dementia (VD)
- Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial (VA-HIT), 154
- WESTCOPS *see* West Scotland Coronary Prevention Study (WESTCOPS)
- West Scotland Coronary Prevention Study (WESTCOPS), 154
- women
 - contraception options, 454–6
 - GDM *see* gestational diabetes (GDM)
 - menopause, 452–4, 456–8
 - PCOS, 439–42
 - pregnancy *see* pregnancy
 - type 1 diabetes, 451–2
 - type 2 diabetes, 452